United Kingdom · Research
Research
Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
2010
Founded
Research
Industry
United Kingdom
Location
347,477,930
Ranking
39 employees
Size
Get full access to view complete information
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
